Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Tobias Tix, Mohammad Alhomoud, Jaromir Tomasik, Gloria Iacoboni, Edward Cliff, Doris Hansen, Saad Usmani, Gilles Salles, Marion Subklewe, Michael Von Bergwelt, Samuel Yamshon, Miguel-Angel Perales, Roni Shouval, David Cordas Dos Santos, Kai Rejeski

Blood (2025) 146 (Supplement 1): 8135.

https://doi.org/10.1182/blood-2025-8135

Published: 2025

Journal Articles

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

Blood (2025) 146 (Supplement 1): 4579.

https://doi.org/10.1182/blood-2025-4579

Published: 2025

Journal Articles

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2182.

https://doi.org/10.1182/blood-2025-2182

Published: 2025

Journal Articles

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

Blood (2025) 146 (Supplement 1): 2181.

https://doi.org/10.1182/blood-2025-2181

Published: 2025

Journal Articles

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 2214.

https://doi.org/10.1182/blood-2025-2214

Published: 2025

Journal Articles

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 7574.

https://doi.org/10.1182/blood-2025-7574

Published: 2025

Journal Articles

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

Blood (2025) 146 (Supplement 1): 5852.

https://doi.org/10.1182/blood-2025-5852

Published: 2025

Journal Articles

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Blood (2025) 146 (Supplement 1): 5846.

https://doi.org/10.1182/blood-2025-5846

Published: 2025

Journal Articles

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Blood (2025) 146 (Supplement 1): 5833.

https://doi.org/10.1182/blood-2025-5833

Published: 2025

Journal Articles

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Blood (2025) 146 (Supplement 1): 96.

https://doi.org/10.1182/blood-2025-96

Published: 2025

Journal Articles

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris Hansen, Lauren Peres, Danai Dima, Saurabh Zanwar, Omar Alexis Castaneda Puglianini, Alicia Richards, Mahmoud Gaballa, Oren Pasvolsky, Aimaz Afrough, Brett Reid, Ariel Grajales-Cruz, Zhuoer Xie, Utkarsh Goel, Aishwarya Sannareddy, Christen Dillard, Christopher Ferreri, Shebli Atrash, Cindy Varga, Andrew Portuguese, Hitomi Hosoya, Lekha Mikkilineni, Nilesh Kalariya, Damian Mikulski, Charlotte Wagner, Christopher Cahoon, Peter Cheng, Christian Gordillo, Eli Zolotov, Evguenia Bhurtel, Jeries Kort, Raffaella Cassano Cassano, Shonali Midha, James Davis, Rebecca Gonzalez, Megan Herr, Hamza Hassan, Sneha Purvey, Marcus Geer, Kimberly Green, Fabiana Perna, Hien Liu, Taiga Nishihori, Jack Khouri, Shahzad Raza, Faiz Anwer, Susan Bal, Omar Nadeem, Ciara Louise Freeman, Rahul Banerjee, Leyla Shune, Ran Reshef, Kenneth Shain, Melissa Alsina, Rachid Baz, Douglas Sborov, Peter Voorhees, Larry Anderson, Luciano Costa, Noa Biran, Shaji Kumar, Frederick Locke, Yi Lin, Surbhi Sidana, Krina Patel

Blood (2025) 146 (Supplement 1): 93.

https://doi.org/10.1182/blood-2025-93

Published: 2025

Journal Articles

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Blood (2025) 146 (Supplement 1): 930.

https://doi.org/10.1182/blood-2025-930

Published: 2025

Journal Articles

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Blood (2025) 146 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2025-5802

Published: 2025

Journal Articles

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Blood (2025) 146 (Supplement 1): 269.

https://doi.org/10.1182/blood-2025-269

Published: 2025

Journal Articles

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 6375.

https://doi.org/10.1182/blood-2025-6375

Published: 2025

Journal Articles

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6371.

https://doi.org/10.1182/blood-2025-6371

Published: 2025

Journal Articles

Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition

Doris Hansen, Lin Wang, Fangyi Gu, Teofilia Acheampong, Meghan Podolsky, Jaclyn Davis, Krina Patel

Blood (2025) 146 (Supplement 1): 5771.

https://doi.org/10.1182/blood-2025-5771

Published: 2025

Journal Articles

Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma

Doris Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz, Saurabh Nagar, Lin Fan, Victoria Alegria, Kevin De Braganca, Tamar Lengil, Mukta Sharma, Helen Pai, Matthew Perciavalle, Jessica Maitland, Bruno Emond, Todd Bixby, Zaina Qureshi, Murali Janakiram

Blood (2025) 146 (Supplement 1): 4596.

https://doi.org/10.1182/blood-2025-4596

Published: 2025

Journal Articles

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 6370.

https://doi.org/10.1182/blood-2025-6370

Published: 2025

Journal Articles

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Blood (2025) 146 (Supplement 1): 6362.

https://doi.org/10.1182/blood-2025-6362

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Date

Availability

Hematotoxicity and immune deficits with bispecific antibodies: A systematic review and meta-analysis in lymphoma and multiple myeloma

Supportive care alone is effective for managing low-grade CRS in multiple myeloma patients treated with bispecific antibodies

The real-world safety and efficacy of bispecific t-cell engager therapy in systemic AL amyloidosis

The real-world safety and efficacy of BCMA-directed chimeric antigen receptor T-cell therapy in systemic AL amyloidosis

Bridging therapy response and low pre-lymphodepletion plasma cell burden are associated with improved safety and efficacy outcomes of ciltacabtagene autoleucel in multiple myeloma

Oral Care™ kit as a prophylaxis for talquetamab-associated toxicities in patients with Relapsed/Refractory multiple myeloma

Subsequent primary malignancies after CAR-T therapy: A study from the US multiple myeloma immunotherapy consortium

ClonoSEQ MRD negativity at day 90 is a strong predictor for progression-free and overall survival after BCMA-directed CAR T-cell therapy for relapsed multiple myeloma.

Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis

Rapid peak CAR-T expansion is associated with delayed neurotoxicity following ciltacabtagene autoleucel in multiple myeloma

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

Incidence of CMV-reactivation in multiple myeloma patients receiving bispecific antibodies

Safety and efficacy of AZD0120, a BCMA/CD19 dual-targeting CAR T-cell therapy, in relapsed/refractory multiple myeloma: Preliminary Results from the DURGA-1 Phase 1b/2 study

Safety and efficacy of BCMA directed CAR-T therapy in older patients (Aged ≥ 75) with relapsed or refractory multiple myeloma (RRMM)

Impact of pre-existing psychiatric conditions on toxicity and outcomes of patients after BCMA-directed CAR-T cell therapy

Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition

Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma

Impact of pre-existing central nervous system conditions and cognitive impairments on toxicity and outcomes after BCMA-directed CAR-T cell therapy

Impact of autoimmune disease on outcomes after BCMA-directed CAR-T cell therapy for patients with multiple myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only